TAIJI GROUP(SH:600129) Guohai Securities·2026-03-30 14:52Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][6]. Core Insights - The company experienced significant revenue decline in 2025, with total revenue of 10.5 billion yuan, down 15.23% year-on-year, while net profit attributable to shareholders surged by 352.38% to 120 million yuan [2][5]. - The report highlights a strategic transformation in industrial marketing, aiming for stable growth during the "14th Five-Year Plan" period, focusing on enhancing product strategy, academic construction, and brand development [5][6]. - The company is expected to see revenue growth in the coming years, with projections of 11.20 billion yuan in 2026, 12.17 billion yuan in 2027, and 12.98 billion yuan in 2028, alongside net profit forecasts of 376 million yuan, 500 million yuan, and 652 million yuan respectively [7][8]. Financial Performance Summary - In 2025, the company reported a revenue of 10.5 billion yuan, with a breakdown showing pharmaceutical manufacturing at 5.2 billion yuan (down 26.11%) and pharmaceutical commerce at 6.21 billion yuan (down 7.86%) [5]. - The company’s net profit margin is projected to improve significantly, with a return on equity (ROE) forecasted to rise from 3% in 2025 to 13% by 2028 [8]. - The price-to-earnings (P/E) ratio is expected to decrease from 82.05 in 2025 to 14.22 by 2028, indicating improved valuation as profitability increases [7][8].